You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

1684 Results
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
Exceptional Access Program
    niraparib / abiraterone - For the treatment of metastatic castration resistant prostate cancer in patients with a BRCA mutation
ODB - General Benefit
    prednisone
Jun 2025
Regimen
Cancer Type:
Sarcoma, 
Desmoid Tumour
Intent: Curative
Aug 2019
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Adjuvant
Apr 2023
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Adjuvant, Palliative
Funding:
ODB - General Benefit
    capecitabine
Apr 2023
Regimen
Cancer Type:
Gastrointestinal, 
Anus
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Apr 2023
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Apr 2023
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Adjuvant
Funding:
ODB - General Benefit
    capecitabine
Apr 2023
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Adjuvant
Funding:
ODB - General Benefit
    capecitabine
Apr 2023
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Intent: Adjuvant, Palliative
Jun 2019
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Adjuvant, Palliative
Sep 2019
Regimen
Cancer Type:
Gynecologic, 
Cervix
Intent: Curative
Jan 2018

Pages